Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
User-agent: * Crawl-delay: |
Title | Zentalis |
Description | Home We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of |
Keywords | N/A |
WebSite | zentalis.com |
Host IP | 23.235.200.4 |
Location | United States |
Site | Rank |
US$23,409,142
Last updated: 2023-05-04 14:08:25
zentalis.com has Semrush global rank of 452,144. zentalis.com has an estimated worth of US$ 23,409,142, based on its estimated Ads revenue. zentalis.com receives approximately 2,701,055 unique visitors each day. Its web server is located in United States, with IP address 23.235.200.4. According to SiteAdvisor, zentalis.com is safe to visit. |
Purchase/Sale Value | US$23,409,142 |
Daily Ads Revenue | US$21,609 |
Monthly Ads Revenue | US$648,254 |
Yearly Ads Revenue | US$7,779,038 |
Daily Unique Visitors | 180,071 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
zentalis.com. | A | 599 | IP: 23.235.200.4 |
zentalis.com. | NS | 3600 | NS Record: ns14.domaincontrol.com. |
zentalis.com. | NS | 3600 | NS Record: ns13.domaincontrol.com. |
zentalis.com. | MX | 3600 | MX Record: 20 d204719b.ess.barracudanetworks.com. |
zentalis.com. | MX | 3600 | MX Record: 50 zentalis-com.mail.protection.outlook.com. |
zentalis.com. | MX | 3600 | MX Record: 0 d204719a.ess.barracudanetworks.com. |
zentalis.com. | TXT | 1800 | TXT Record: docusign=0b19416b-8d15-4ad5-8b23-9acd68fa6e9b |
zentalis.com. | TXT | 1800 | TXT Record: v=spf1 include:spf.protection.outlook.com -all |
zentalis.com. | TXT | 1800 | TXT Record: atlassian-domain-verification=I3nUTa06QPkBxRRmEQBYAIQy10rpGR5CweQEKM/i2o/IhKTLcZYpqDOAZWY609uG |
Search: Search Toggle Navigation Search: Search Submit About Us Our Company Management Team Board of Directors Scientific Advisory Board Partners & Collaborations Contact Our Pipeline Pipeline Azenosertib (ZN-c3) ZN-d5 BCL-xL Degrader Clinical Trials Our Approach Integrated Discovery Engine Supporting Publications Investors & Media Investor Home News & Events Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage Financials & Filings SEC Filings Corporate Governance Documents & Charters Management Team Board of Directors Scientific Advisory Committee Committee Composition Investor Resources Investor FAQs Investor Contact Email Alerts Careers Why Zentalis? Job Opportunities Home Creating Differentiated Small Molecules Designed to Improve the Lives of Cancer Patients About Zentalis We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of |
HTTP/1.1 406 Not Acceptable Server: nginx/1.21.3 Date: Tue, 26 Oct 2021 15:34:10 GMT Content-Type: text/html; charset=iso-8859-1 Content-Length: 300 Connection: keep-alive |
Domain Name: ZENTALIS.COM Registry Domain ID: 2451730655_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2019-11-05T18:39:36Z Creation Date: 2019-11-05T18:39:36Z Registry Expiry Date: 2024-11-05T18:39:36Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS13.DOMAINCONTROL.COM Name Server: NS14.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2021-09-14T15:22:06Z <<< |